Graypoint LLC’s KALA BIO KALA Stock Holding History

Graypoint LLC’s Portfolio KALA Stock Details KALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-195	Closed	-$672K	–	318
2022 Q1	$672K	Buy	+195	New	+$511K	0.07%	169

Other funds holding KALA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BOTOTLSJU

Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Graypoint LLC's KALA Position: Q2 2022 in Review

Graypoint LLC sold out of KALA BIO (KALA) in Q2 2022, closing a stake of 195 shares — an estimated $672K sold.

Graypoint LLC first reported a position in KALA in Q1 2022 and held it in 1 quarter. The position peaked at $672K in Q1 2022. 63 funds tracked by Wall St. Rank hold KALA as of Q2 2022.

Graypoint LLC reported no remaining KALA BIO position as of Q2 2022 after selling out during the quarter.
Graypoint LLC sold 195 KALA BIO shares in Q2 2022, an estimated $672K.
Graypoint LLC first reported a position in KALA BIO in Q1 2022 and held it in 1 quarter.
Graypoint LLC's KALA BIO position peaked at $672K in Q1 2022.
63 funds tracked by Wall St. Rank held KALA BIO as of Q2 2022.

Based on Graypoint LLC's 13F filing for Q2 2022, filed 1 Aug 2022.